EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared Transgene to start a phase 1 trial of its personalized immunotherapy TG4050 in ovarian cancer patients. NEC is co-financing the cancer vaccine trial. Release

> UniQure posted updated data on its hemophilia B gene therapy. The data show the high Factor IX activity seen early in the study has been sustained up to six months. Statement

> A phase 2 trial of Modus Therapeutics’ sickle cell disease drug failed to show a meaningful benefit. The setback led Modus to weigh its options for further development of the asset. Release  

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> TreeFrog Therapeutics raised €7 million ($7.8 million). The French startup aims to move one of its cell therapy research programs into humans in 2024. Statement 

> Pfizer nominated a preclinical development candidate under its collaboration with Sosei Heptares, triggering a $3 million milestone payment. The partners are yet to disclose the target of the small molecule. Release  

> Ixaltis completed phase 2 development of its urinary incontinence drug, litoxetine, setting the French biotech up to move into phase 3. Statement  

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.